CONTRIBUTORS

Neuro-oncology p. 1442-1448 December 2020, Vol.26, No.6 doi: 10.1212/01.CON.0000724532.21459.46
CONTRIBUTORS
BROWSE ARTICLES

Tracy T. Batchelor, MD, MPH Guest Editor

Neurologist-in-Chief, Chair, Department of Neurology, Brigham and Women’s Hospital, Miriam Sydney Joseph Professor of Neurology, Harvard Medical School, Boston, Massachusetts

Relationship Disclosure: Dr Batchelor has received personal compensation for serving on the scientific advisory board for GenomiCare and as an author for UpToDate, Inc, research/grant support from the National Institutes of Health (1P50CA165962-01), and publishing royalties from UpToDate, Inc.

Unlabeled Use of Products/Investigational Use Disclosure: Dr Batchelor reports no disclosure.

Adrienne Boire, MD, PhD

Assistant Attending Neurologist, Department of Neurology; Assistant Member, Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York

Relationship Disclosure: Dr Boire has received research/grant support from the Damon Runyon Cancer Research Foundation, the Pershing Square Sohn Cancer Research Alliance, The Pew Charitable Trusts, and the W. M. Keck Foundation.

Unlabeled Use of Products/Investigational Use Disclosure: Dr Boire discusses the unlabeled/investigational intrathecal use of trastuzumab to treat leptomeningeal metastasis.

Neil A. Busis, MD, FAAN

Associate Chair of Technology and Innovation; Clinical Professor, Department of Neurology; Clinical Director of Clinical Affairs, Telehealth Program, NYU Langone Health, New York, New York

Relationship Disclosure: Dr Busis serves as an alternate CPT advisor for and has received personal compensation for speaking engagements from the American Academy of Neurology.

Unlabeled Use of Products/Investigational Use Disclosure: Dr Busis reports no disclosure.

Luana Ciccarelli, CPC, CRC

Senior Manager, Reimbursement and Coding, American Academy of Neurology

Relationship Disclosure: Ms Ciccarelli reports no disclosure.

Unlabeled Use of Products/Investigational Use Disclosure: Ms Ciccarelli reports no disclosure.

Bruce H. Cohen, MD, FAAN

Professor of Pediatrics and Professor of Integrative Medical Sciences, Northeast Ohio Medical University, Rootstown; Director, Neurodevelopmental Science Center, Akron Children’s Hospital, Akron, Ohio

Relationship Disclosure: Dr Cohen serves as an associate editor for Continuum: Lifelong Learning in Neurology, Mitochondrion, and Pediatric Neurology; as the chair of the scientific and medical advisory board of the United Mitochondrial Disease Foundation; and as a consultant for Minovia Therapeutics, Modis Therapeutics (Zogenix), NeuroVive Pharmaceutical AB, Reneo Pharmaceuticals, Inc, and the US Department of Health & Human Services, and as a CPT consultant for the American Academy of Neurology. Dr Cohen receives research/grant support from BioElectron Technologies (PTC Therapeutics), the National Institutes of Health (U54NS078059), and Stealth BioTherapeutics Inc, and publishing royalties from Elsevier and has received personal compensation for speaking engagements from the American Academy of Neurology and Stealth BioTherapeutics.

Unlabeled Use of Products/Investigational Use Disclosure: Dr Cohen reports no disclosure.

Howard Colman, MD, PhD, FAAN

Jon M. Huntsman Presidential Chair in Neuro-Oncology; Professor, Departments of Neurosurgery, Neurology, and Internal Medicine (Oncology), Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah

Relationship Disclosure: Dr Colman has served as an associate editor for Neuro-Oncology and on the editorial board for Neuro-Oncology Practice and has received personal compensation for serving on the advisory boards for AbbVie Inc, Bayer AG, Deciphera Pharmaceuticals, Inc, Forma Therapeutics, Karyopharm, NewLink Genetics Corporation, and Orbus Therapeutics, Inc, and as a consultant for Best Doctors/Teladoc Health, Inc, and Private Health. Dr Colman has received grant support from the Alliance for Clinical Trials in Oncology (LAPS-UT003), The Hope Foundation, the Huntsman Cancer Foundation, the Musella Foundation For Brain Tumor Research & Information, Inc, the National Cancer Institute (R21CA245577), the National Institute of Neurological Disorders and Stroke (1R01NS107810), and SWOG Cancer Research Network and has received research support from NewLink Genetics Corporation, Orbus Therapeutics, Inc, and Plexxikon.

Unlabeled Use of Products/Investigational Use Disclosure: Dr Colman discusses the unlabeled/investigational use of agents targeting mutations/alterations in BRAF (including vemurafenib), EGFR, FGFR, IDH, and NTRK to treat gliomas that harbor alterations in those genes and the use of checkpoint inhibitors, chimeric antigen receptor T cells, and pembrolizumab to treat glioblastoma.

Jorg Dietrich, MD, PhD, FAAN

Associate Professor of Neurology, Harvard Medical School; Clinical Director, Division of Neuro-oncology, Department of Neurology, Massachusetts General Hospital, Boston, Massachusetts

Relationship Disclosure: Dr Dietrich has received personal compensation for serving as a consultant for Blue Earth Diagnostics and Unum Therapeutics and publishing royalties from Wolters Kluwer N.V.

Unlabeled Use of Products/Investigational Use Disclosure: Dr Dietrich reports no disclosure.

Eoin P. Flanagan, MBBCh

Consultant in Neurology and Laboratory Medicine and Pathology; Associate Professor of Neurology, Mayo Clinic College of Medicine and Science, Rochester, Minnesota

Relationship Disclosure: Dr Flanagan has received research/grant support from MedImmune/Viela Bio.

Unlabeled Use of Products/Investigational Use Disclosure: Dr Flanagan discusses the unlabeled/investigational use of azathioprine, corticosteroids, cyclophosphamide, IV immunoglobulin, methotrexate, mycophenolate mofetil, plasma exchange, rituximab, and tocilizumab for the treatment of paraneoplastic disorders of the nervous system.

Deborah A. Forst, MD

Instructor in Neurology, Harvard Medical School; Neuro-Oncologist, Pappas Center for Neuro-Oncology, Massachusetts General Hospital Cancer Center, Boston, Massachusetts

Relationship Disclosure: Dr Forst has received personal compensation for speaking engagements from the American Academy of Neurology and NYU Langone Medical Center and for travel from INOVIO Pharmaceuticals and has received research/grant support from the American Cancer Society, Conquer Cancer/The American Society of Clinical Oncology (ASCO) Foundation, and the Palliative Care Research Cooperative Group.

Unlabeled Use of Products/Investigational Use Disclosure: Dr Forst reports no disclosure.

Christian Grommes, MD

Associate Attending Neurologist, Department of Neurology, Memorial Sloan Kettering Cancer Center; Assistant Professor, Department of Neurology, Weill Cornell Medical College, New York, New York

Relationship Disclosure: Dr Grommes has received personal compensation for serving as a consultant for Boston Scientific Corporation, Gilead Services, Inc, and Ono Pharmaceutical Co, Ltd.

Unlabeled Use of Products/Investigational Use Disclosure: Dr Grommes discusses the unlabeled/investigational use of immune checkpoint inhibitors for the treatment of primary central nervous system lymphoma.

Eudocia Q. Lee, MD, MPH

Senior Physician, Dana-Farber Cancer Institute; Neuro-oncologist, Brigham and Women’s Hospital; Assistant Professor of Neurology, Harvard Medical School, Boston, Massachusetts

Relationship Disclosure: Dr Lee has served as a consultant for prIME Oncology and has received publishing royalties from Wolters Kluwer N.V. and an honorarium from Medlink Inc.

Unlabeled Use of Products/Investigational Use Disclosure: Dr Lee discusses the use of checkpoint inhibitors for the treatment of progressive multifocal leukoencephalopathy.

Rimas V. Lukas, MD

Associate Chief, Neuro-oncology Division; Ambulatory Medical Director, Department of Neurology, Northwestern University, Chicago, Illinois

Relationship Disclosure: Dr Lukas has received personal compensation for serving on the scientific advisory board and speakers bureau for Novocure, as a senior editor for MedLink Inc, on the medical review board for EBSCO Information Services, and as a consultant for Eisai Co, Ltd. Dr Lukas has received research/grant support from BrainUp, Bristol-Myers Squibb Company, and the National Cancer Institute (P50CA221747) and has reviewed medical records for Anderson Rasor & Partners, LLP.

Unlabeled Use of Products/Investigational Use Disclosure: Dr Lukas discusses the unlabeled/investigational use of therapies targeting NF2, AKT, SMO, and BRAF pathways in meningiomas and craniopharyngiomas.

Michelle Monje, MD, PhD

Associate Professor of Neurology and Neurological Sciences, Stanford University, Palo Alto, California

Relationship Disclosure: Dr Monje serves on the editorial advisory boards for Cancer Cell, Neuro-Oncology, and Neuron; has received personal compensation for serving on the scientific advisory board for Cygnal Therapeutics; and has received research/grant support from Cancer Research UK, the National Cancer Institute (P50CA165962), the National Institute of Neurological Disorders and Stroke (R01NS092597), the National Institutes of Health (DP1NS111132), and the Robert J. Kleberg Jr and Helen C. Kleberg Foundation.

Unlabeled Use of Products/Investigational Use Disclosure: Dr Monje discusses the unlabeled/investigational use of medications for pediatric brain tumors, none of which are approved by the US Food and Drug Administration.

Maciej M. Mrugala, MD, PhD, MPH, FAAN

Associate Professor; Director, Comprehensive Neuro-oncology Program; Co-director, Neurofibromatosis Clinic, Mayo Clinic and Mayo Clinic Cancer Center, Phoenix, Arizona

Relationship Disclosure: Dr Mrugala has served as a member of the advisory board for the National Comprehensive Cancer Network and has received research/grant support from Arbor Pharmaceuticals.

Unlabeled Use of Products/Investigational Use Disclosure: Dr Mrugala discusses the unlabeled/investigational use of therapies targeting NF2, AKT, SMO, and BRAF pathways in meningiomas and craniopharyngiomas.

Sonia Partap, MD

Clinical Associate Professor of Neurology and Neurological Sciences, Lucile Packard Children’s Hospital at Stanford, Stanford University, Palo Alto, California

Relationship Disclosure: Dr Partap has served on advisory boards for Bayer AG and Fennec Pharmaceuticals and as a consultant for Gerson Lehrman Group, Inc. Dr Partap has received personal compensation for speaking engagements from the American Academy of Neurology, the American Academy of Pediatrics, the Medical Education Speakers Network, and the Society for Neuro-Oncology and research/grant support from AbbVie Inc and the National Institutes of Health/National Cancer Institute (5 UM1 CA081457 18).

Unlabeled Use of Products/Investigational Use Disclosure: Dr Partap discusses the unlabeled/investigational use of medications for pediatric brain tumors, none of which are approved by the US Food and Drug Administration.

Scott R. Plotkin, MD, PhD

Armenise-Harvard Professor of Neurology, Harvard Medical School; Executive Director of the Stephen E. and Catherine Pappas Center for Neuro-Oncology, Cancer Center and Department of Neurology, Massachusetts General Hospital, Boston, Massachusetts

Relationship Disclosure: Dr Plotkin has served on research and clinical care advisory boards for the Children’s Tumor Foundation and has received personal compensation as a consultant for AstraZeneca, NFlection Therapeutics, Inc, NF2 Therapeutics, Inc, and SonALAsense and research/grant support from the Children’s Tumor Foundation, the Department of Defense (W81XWH-17-1-0121 and W81XWH-16-1-0103), the National Institutes of Health (5R01CA201130-04, 5K12CA090354-19, 9R13CA236402-03, and 2R42CA192600-02), and the Neurofibromatosis Therapeutic Acceleration Program. Dr Plotkin has held stock in NFlection Therapeutics, Inc, and NF2 Therapeutics, Inc.

Unlabeled Use of Products/Investigational Use Disclosure: Dr Plotkin discusses the unlabeled/investigational use of bevacizumab, everolimus, lapatinib, ridaforolimus, selumetinib, and temsirolimus for the treatment of familial nervous system tumors.

Roy E. Strowd III, MD, MEd, MS

Co-director, Comprehensive Neurofibromatosis and Tuberous Sclerosis Clinics, Comprehensive Cancer Center; Associate Professor, Departments of Neurology, Internal Medicine, and the Translational Sciences, Wake Forest School of Medicine, Winston-Salem, North Carolina

Relationship Disclosure: Dr Strowd has served a consultant for Monteris Medical, Nanobiotix, and Novocure and as a section editor for Neurology. Dr Strowd has received research/grant support from the American Academy of Neurology; the American Society of Clinical Oncology; Jazz Pharmaceuticals, Inc; and the Southeastern Brain Tumor Foundation.

Unlabeled Use of Products/Investigational Use Disclosure: Dr Strowd discusses the unlabeled/investigational use of bevacizumab, everolimus, lapatinib, ridaforolimus, selumetinib, and temsirolimus for the treatment of familial nervous system tumors.

Raissa Villanueva, MD, MPH, FAAN

Associate Chair, Neurology Ambulatory Operations, University of Rochester Medical Center, Rochester, New York

Relationship Disclosure: Dr Villanueva has received honoraria for speaking engagements and compensation for CPT consulting from the American Academy of Neurology.

Unlabeled Use of Products/Investigational Use Disclosure: Dr Villanueva reports no disclosure.

Self-Assessment and CME Test Writers

Adam G. Kelly, MD, FAAN

Associate Professor of Neurology; Director of Teleneurology and Regional Neurology, University of Rochester, Rochester, New York

Relationship Disclosure: Dr Kelly has received personal compensation as CME editor of Neurology.

Unlabeled Use of Products/Investigational Use Disclosure: Dr Kelly reports no disclosure.

James W. M. Owens Jr, MD, PhD

Associate Professor of Neurology, Adjunct Associate Professor of Pediatrics, University of Washington School of Medicine, Seattle, Washington

Relationship Disclosure: Dr Owens has served as CME co-editor for Neurology and has received publishing royalties from UpToDate, Inc.

Unlabeled Use of Products/Investigational Use Disclosure: Dr Owens reports no disclosure.

Peer Reviewers

Continuum is a peer-reviewed journal. For each review article, at least two peer reviewers anonymous to the authors are selected to assess quality, balance, and clarity of articles. Critical reviews of the material at other stages of the development process may also be conducted. Upon receipt of final manuscripts, the editor-in-chief makes the final decision as to whether material is suitable for publication in Continuum.

We are thankful to the following peer reviewers of articles published during 2020 for the immense work they put in and their excellent assessment of manuscripts to help ensure that only the highest-quality information is published in Continuum:

Ashley Aaroe, MD

Zarmeneh Aly, MD

Chandana Chauhan, MD

Charles Esenwa, MD

Ana Felix, MD, FAAN

Daniel Freedman, MD

Dimitrio Giannakidis, MD

Ajmal Gilani, MD, FAAN

Carrie Grouse, MD

Agostinoho Guerra, MD

Shafali Jeste, MD, FAAN

Edward Labin, MD

Sara LaHue, MD

John Morren, MD

Krishna Mylavarapu, MD

Alejandro Rabinstein, MD, FAAN

Ronald Sims, MD

© 2020 American Academy of Neurology.